Press releases
- Press releases
- Browse
Press releases
Two papers on Embil's novel triple-active topical products (Neo-Penotran® Forte and Neo-Penotran® Forte-L) have been accepted for presentation at the 4'th World Conference on Vaginitis, Costa Rica, 10-13 Jan 2004 More
Morphochem AG and Xenogen Corp. today announced that both companies have entered into a research collaboration to discover targets and develop compounds effective against bacterial biofilms. More
Bavarian Nordic A/S and Schering AG signed today an agreement whereby Bavarian Nordic acquires the wholly-owned subsidiary of Schering, GTB GenTherapeutika Berlin-Buch GmbH, in Berlin, Germany. More
Morphochem and GBF have entered into a research collaboration in the area of cancer research, the objective of which is to develop new therapeutics using tubulysins. More
RiboTargets, the structure-based drug discovery company that develops novel cancer and anti-bacterial therapeutics, announced today that it has extended its exclusive license with ASINEX for a further three years. More
First and Only Water-Optional Handwash Helps Fight Nosocomial Infections in Hospitals; Helps Standardize Hospital Handwashing, Increases Efficacy, Improves Handwashing Compliance More
Bavarian Nordic A/S has been awarded Part B of the US government's program to further develop MVA-BN as a safe third-generation smallpox vaccine. The award has a potential value of $23 million. More
On World AIDS Day 2003, the leading pharmaceutical R&D database Pharmaprojects reviews the current status of AIDS drug development, and highlights the urgent need to expedite the introduction of new and effective medicines. Data released last wee More
Bavarian Nordic acquires a pharmaceutical production facility and establishes its own production of vaccines. The facility will be one of Europe's largest production sites for vaccines with the capacity to produce up to 120 million doses per year. More
BioCryst has been awarded a $600,000 Phase I SBIR Advanced Technology Grant to optimize Hepatitis C virus NS5B Polymerase Inhibitors More
Related Reports
Market Research Reports provided by reports.iptechex.com
Nov 2010 - 40 pages - $500
Oct 2009 - 17 pages - $500
Nov 2011 - 7 pages - $3,835
Jun 2006 - 1458 pages - $2,495
Oct 2011 - 150 pages - $3,500
Nov 2010 - 40 pages - $500
Nov 2010 - 40 pages - $500
Mar 2011 - 32 pages - $250
Nov 2010 - 7 pages - $500
Apr 2011 - $75
Your selection
Browse By
- Industry sector
- Academic/Research
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Non-profit org./Government
- Pharmaceutical
- Research tools
- Service
- Therapeutic target
- Aspergillosis
- Bronchitis
- Candidiasis
- Chicken pox
- Chlamydia
- Cholera
- Chronic fatigue syndrome
- Creutzfeldt-Jakob disease
- Diarrhea, bacterial
- Diphtheria
- Ebola hemorrhagic fever
- Encephalitis
- Epstein-Barr virus
- Fever
- Food poisoning
- Gastroenteritis
- Genital warts
- German measles
- Gonorrhea
- Hepatitis A/B
- Hepatitis C/D/E
- HIV
- Infection, bacterial(other)
- Infection, fungal (other)
- Infection, viral (other)
- Infectious disease (other)
- Influenza
- Legionnaire's disease
- Leprosy
- Lyme disease
- Malaria
- Measles
- Meningitis, bacterial
- Meningitis, cryptococcal
- Meningitis, neoplastic
- Meningitis, viral
- Mumps
- Pneumonia
- Polio
- Protozoal diseases (other)
- Pseudomonas lung infection
- Rabies
- Rhinovirus (common cold)
- Rotavirus infection
- Sepsis
- Shingles
- Sinusitis
- Streptococcal infections
- Tetanus
- Trypanosomiasis
- Tuberculosis
- Typhoid
- Urinary tract infection
- Warts
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us